COMPARATIVE EFFECTIVENESS RESEARCH

Prioritization of Comparative Effectiveness Research Topics in Hospital Pediatrics

Ron Keren, MD, MPH; Xianqun Luan, MS; Russell Localio, PhD; Matt Hall, PhD; Lisa McLeod, MD, MSCE; Dingwei Dai, PhD; Rajendu Srivastava, MD, FRCPC, MPH; for the Pediatric Research in Inpatient Settings (PRIS) Network

Objective: To use information about prevalence, cost, and variation in resource utilization to prioritize comparative effectiveness research topics in hospital pediatrics.

Design: Retrospective analysis of administrative and billing data for hospital encounters.

Setting: Thirty-eight freestanding US children's hospitals from January 1, 2004, through December 31, 2009.

Participants: Children hospitalized with conditions that accounted for either 80% of all encounters or 80% of all charges.

Main Outcome Measures: Condition-specific prevalence, total standardized cost, and interhospital variation in mean standardized cost per encounter, measured in 2 ways: (1) intraclass correlation coefficient, which represents the fraction of total variation in standardized costs per encounter due to variation between hospitals; and (2) number of outlier hospitals, defined as having more than 30% of encounters with standardized costs in either the lowest or highest quintile across all encounters. **Results:** Among 495 conditions accounting for 80% of all charges, the 10 most expensive conditions accounted for 36% of all standardized costs. Among the 50 most prevalent and 50 most costly conditions (77 in total), 26 had intraclass correlation coefficients higher than 0.10 and 5 had intraclass correlation coefficients higher than 0.30. For 10 conditions, more than half of the hospitals met outlier hospital criteria. Surgical procedures for hypertrophy of tonsils and adenoids, otitis media, and acute appendicitis without peritonitis were high cost, were high prevalence, and displayed significant variation in interhospital cost per encounter.

Conclusions: Detailed administrative and billing data can be used to standardize hospital costs and identify high-priority conditions for comparative effectiveness research—those that are high cost, are high prevalence, and demonstrate high variation in resource utilization.

Arch Pediatr Adolesc Med. 2012;166(12):1155-1164. Published online October 1, 2012. doi:10.1001/archpediatrics.2012.1266

Author Affiliations are listed at the end of this article. Group Information: The Pediatric Research in Inpatient Settings (PRIS) Network investigators are listed at the end of this article.

ATIENTS, HEALTH CARE PROviders, and payers need better evidence about the comparative effectiveness of medical therapies and health care delivery models. The American Recovery and Reinvestment Act of 2009 acknowledged this need and allocated hundreds of millions of dollars to the National Institutes of Health, the Agency for Healthcare Research and Quality, and the newly established Patient-Centered Outcomes Research Institute to fund comparative effectiveness research (CER).1 The Patient-Centered Outcomes Research Institute is a public-private partnership whose principal focus will be to formulate and fund a portfolio of CER projects to compare drugs, medical devices, tests, surgical procedures, or health care delivery models. To

achieve the highest return on this investment, it is essential that scientific agencies and institutes such as the Patient-Centered Outcomes Research Institute have a means of prioritizing CER projects. To that end, Congress charged 2 groups—the Institute of Medicine (IOM) Committee on Comparative Effectiveness Research Prioritization² and the Federal Coordinating Council for Comparative Effectiveness Research³—to solicit extensive public input and provide recommendations on priorities for the allocation of these new CER funds.

The Federal Coordinating Council for Comparative Effectiveness Research report focused its recommendations largely on the infrastructure needed to support a national CER effort. However, the IOM committee identified 100 specific re-

WWW.ARCHPEDIATRICS.COM

ARCH PEDIATR ADOLESC MED/VOL 166 (NO. 12), DEC 2012 1155

©2012 American Medical Association. All rights reserved.

search topics that should be prioritized for CER, onefifth of which had relevance to children.⁴ The IOM recommendations were based on tables summarizing prevalence, morbidity, cost, mortality, and variations in treatment for each topic considered—important condition-related criteria that Dubois and Graff⁵ have incorporated into a larger framework for prioritizing CER research topics, which also includes research-related criteria such as the feasibility (cost and time), likelihood of success, and potential impact of the research.

While it is an important step toward establishing a research agenda for CER, the IOM list of priority conditions falls short of what is needed to prioritize CER in pediatrics. Most of the included pediatric priority topics were nonspecific in content and target population (eg, "care coordination programs for children and adults with chronic disease") and all but one focused on care provided in the outpatient setting. The list of pediatric conditions and questions lacking a strong CER evidence base is vast, and many of the pediatric topics that have the greatest impact on overall childhood morbidity, mortality, and health care spending are managed in the hospital setting, which is the locus of rapidly emerging technologies and life-saving or life-extending therapies, especially for medically complex children.⁶ To provide a more detailed and comprehensive view of the pediatric conditions that should be prioritized for CER, focusing specifically on the inpatient setting, we used detailed administrative and billing data from 38 of the largest freestanding children's hospitals in the United States to generate inputs for several of the key condition-specific prioritization criteria included in the prioritization frameworks of the IOM committee and DuBois and Graffprevalence, cost, and variation in care, measured in terms of the variation in resource utilization for children hospitalized with specific conditions.

METHODS

DESIGN AND DATA SOURCE

This study was a retrospective cohort study. The Pediatric Health Information System (PHIS) database contains detailed hospital administrative and billing data from 43 freestanding children's hospitals affiliated with the Children's Hospital Association (formerly known as the Child Health Corporation of America). Details about the PHIS database have been reported previously.⁷ The Institutional Review Board of the Children's Hospital of Philadelphia deemed this study exempt from review under 45 CFR 46.102(f), as the participants were not readily identifiable.

DIAGNOSIS CODE GROUPER

We queried the PHIS database (January 1, 2004, through December 31, 2009) to identify the *International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)* primary discharge diagnosis codes associated with encounters (inpatient, ambulatory surgery, and observation unit) that accounted for either 80% of all encounters or 80% of all charges.

Two of us (R.K. and R.S.) independently reviewed this list of 701 *ICD-9-CM* primary discharge diagnosis codes and grouped them into distinct "conditions" based on whether the initial evaluation and management of the diagnoses are the same across individual codes. Differences in group assignments were resolved by consensus. We further divided the conditions into medical, surgical, or medical/surgical based on whether fewer than 20%, more than 80%, or between 20% and 80%, respectively, of encounters for a particular condition had an *ICD*-*9-CM* principal procedure code for a surgery related to the condition. This process resulted in 255 medical, 231 surgical, and 16 medical/surgical conditions and produced more granular classification of discharge diagnoses than would have been possible using existing classification systems such as diagnosis related groups or related classification systems.

We used the ICD-9-CM procedure codes that were reported for each encounter to further restrict the cohort of children within each condition. For medical and medical/ surgical conditions, we excluded children who had procedures (surgical or nonsurgical) that were unlikely to be related to the medical condition (eg, laparoscopic appendectomy for a child with a primary diagnosis of asthma). For surgical conditions, we included only children who had procedures that were likely to be related to the condition (eg, laparoscopic or open appendectomy for a child with a primary diagnosis of appendicitis). A team of 8 pediatric hospital medicine researchers decided which procedure codes would be used to include or exclude children from the conditionspecific cohorts. The medical and surgical conditions were divided into 4 lists, and 2 researchers were assigned to independently review each list and identify procedure codes that should serve as inclusion or exclusion criteria for a particular condition. The 4 groups reviewed a total of 14534 procedures codes and agreed on inclusion or exclusion of 88% of codes overall. The agreement rates for individual groups were 88%, 90%, 78%, and 96%. Disagreements were resolved through consensus.

DEVELOPING A COST MASTER INDEX

One of our key prioritization factors was variation in the volume of resources used for a particular condition. The idea to focus on variation in resource utilization, rather than variation in adherence to specific quality measures, mirrors the approach adopted by the Dartmouth Atlas of Health Care, which has shown repeatedly that high-intensity care is not always associated with better quality or outcomes and is often a product of excess local capacity (supply-sensitive care) and/or inadequate evidence or efforts to support lower-intensity care (preference-sensitive care).8 The variation identified in Dartmouth Atlas of Health Care studies is used to signal conditions or procedures for which there may be opportunities to improve the quality and/or value derived from health care spending,9 a fundamental goal of CER. Focusing on variation in resource utilization also provided us with a single common metric to study variation across all pediatric inpatient conditions and compare the magnitude of that variation across conditions.

Because we sought to use hospitalization costs as a surrogate for volume of resources expended, we needed to standardize the cost of individual items to remove the high interhospital variation in item costs. To calculate standardized costs per item, we first tabulated the line-item charges and number of billed units for every Clinical Transaction Classification (CTC) code in every hospital billing record. We then computed the cost per CTC for each line item using hospital- and departmentspecific ratios of cost to charges (RCCs), the CTC charge, and the number of billed CTC units. The charges listed in the PHIS database already adjust for the wage and price index (published annually in the *Federal Register*). All costs were then inflated to 2009 dollars using the medical care services compo-

nent of the Consumer Price Index.¹⁰ Next, we calculated the median cost for every CTC code within each hospital. Finally, we defined the standardized unit cost for each CTC code as the median of hospital median unit costs. The standardized unit costs for a total of 20 903 CTC codes were tabulated in a cost master index (CMI). Using the standardized unit costs from the CMI, we recalculated the total hospitalization cost for every admission (n=3 482 709) by multiplying the CMI cost by the number of units for each CTC appearing in the hospital bill and then summing the standardized costs of each line item in every hospital bill.

DATA ISSUES

A total of 43 hospitals contributed data to the PHIS database during the 6-year study period (January 1, 2004, through December 31, 2009). Several issues affected the final data included in the analysis.

Missing Billing Data

Two hospitals were excluded from the analysis because they did not submit any billing data and 1 hospital was excluded because it submitted only 1 year of billing data, leaving a total of 40 hospitals that submitted billing data during the study period: 34 that submitted billing data for the entire 6-year study period, 4 that started submitting billing data in 2005, and 2 that started in 2006. On further review of the billing data from these hospitals, we discovered 13 quarters (distributed across individual hospitals) when 10% or more of the records were missing billing data, and we excluded these from the analysis as well.

Missing Hospital- and Department-Specific RCCs

The PHIS billing data are divided into 29 charge departments, each with a hospital- and year-specific RCC that we used to convert charges into costs. Two hospitals submitted no RCC information and were excluded from the analysis, leaving us with a total of 38 hospitals and 221 hospital-years' worth of data for the calculation of standardized costs for the CMI and the analysis of interhospital variation in costs for individual conditions. We expected 6409 department-specific RCCs (29 department-specific RCCs \times 221 hospital-years), but 454 (7%) were missing. We used a formal imputation strategy (chained equations) to impute these missing department-specific RCCs.¹¹

Noninteger Units or Unit Counts That Were Unreasonably High or Low for CTC Codes in Some Bills

Based on manual review, we determined that noninteger units or unit counts that were unreasonably high or low for CTC codes in some bills reflected hospital-specific coding errors or idiosyncrasies. We simply replaced the line-item cost calculated by multiplying the number of units by CMI unit cost with the reported charge (multiplied by the RCC) when the suspect cost was either more than 3 times or less than one-third of the replacement cost. This substitution was necessary in fewer than 5% of all the billed items.

STATISTICAL ANALYSIS

We calculated the standardized costs for each encounter of a child with one of the conditions (medical, surgical, and medical/ surgical) included in our *ICD-9-CM* grouper. For each condition, we evaluated the overall distribution of costs per encoun-

ter. To reduce the influence of costs for children with complex chronic conditions, who often use more resources for reasons unrelated to their reason for admission, we identified and excluded extreme cost outliers (top 1% of charges within each condition). For some analyses, we adjusted the standardized costs for patient age (<30 days; \geq 30 days and <1 year; \geq 1 year and <5 years; \geq 5 years and <13 years; \geq 13 years and <17 years; \geq 18 years), sex, race (white, black, other), presence of a complex chronic condition,¹² all patient refined diagnosis related group severity level, and patient type (inpatient, ambulatory surgery, and observation status).

For each condition, we calculated the mean, median, and quintiles of standardized (as well as adjusted standardized) cost per encounter. We generated bin plots to show the number and proportion of patients at a particular hospital whose standardized (and adjusted standardized) cost per encounter was within 1 of the 5 quintiles. We also generated box plots to demonstrate the within- and across-hospital variation in mean standardized cost per encounter for each condition. For a simple and easily interpretable estimation of the degree of variation in standardized cost per encounter across hospitals, for each condition we counted the number of hospitals with more than 30% of their encounters in either the highest or lowest quintile of overall standardized cost per encounter (defined as outlier hospitals). As another measure of variation, we estimated for each condition the intraclass correlation coefficient (ICC), which in the context of our analysis equals the amount of variation in outcome (costs) across hospitals as a fraction of total variation in costs, where the total variation includes withinhospital and across-hospital dispersion of costs.13 As such, it presents a natural measure: the ICC approaches 0 if variation across hospitals is small, and the ICC approaches 1 as hospitals begin to account for all variation of costs. For different clinical conditions, the ICC therefore measures across-hospital variation on a common metric. The ICCs were calculated using a mixed-effects model with hospital as a random intercept and the patient characteristics listed earlier as fixed effects. All data management and analyses were conducted using SAS version 9.2 statistical software (SAS Institute, Inc) and Stata version 11.1 statistical software (StataCorp LP).

RESULTS

The **Table** shows the 50 most prevalent and 50 most costly conditions (total of 77 altogether) sorted by cumulative standardized cost across hospitals. Conditions ranked high in cumulative cost because they were either very prevalent (eg, pneumonia) or very expensive on a cost per encounter basis (eg, respiratory distress syndrome in the newborn). The 10 most expensive conditions accounted for 36% of all costs among the 495 conditions included in our original sample.

Of the 77 most prevalent and/or costly conditions, 26 had ICCs higher than 0.10 and 5 had ICCs higher than 0.30 after adjusting costs for patient demographic characteristics, presence of a complex chronic condition, all patient refined diagnosis related group severity level, and admission type (Table). Our outlier analysis identified many conditions for which a large number of hospitals had a high proportion of high- or low-cost hospitalizations, including 10 conditions for which more than half of the hospitals had more than 30% of encounters with costs in either the lowest or highest quintile of overall costs. Conditions that met all the prioritization criteria (prevalent, high cost, and high variation in interhospital cost per

Table. Prevalence, Cost, and Variation in Standardized Cost for the 50 Most Prevalent and 50 Most Costly Pediatric Inpatient Conditions

			Rank	- Encounters, e No.	Sta	andardized	Cost, \$	Standar All 495	dized Cost for Conditions, %		Ou Hospita	tlier Ils, No. ^a
Condition	Туре	Cost	Prevalence		Per Encounter	Total, Millions	Cumulative, Millions	Total	Cumulative	ICC ^a	Low- Cost	High- Cost
Respiratory distress syndrome in newborn	М	1	37	16 806	72 923	1226	1226	6.49	6.49	0.07	12	4
Pneumonia	М	2	5	106 792	8293	886	2111	4.69	11.18	0.04	5	4
Chemotherapy	М	3	7	90 694	8746	793	2904	4.20	15.38	0.12	7	5
Acute respiratory failure	М	4	42	15 246	41 146	627	3532	3.32	18.70	0.05	2	4
Scoliosis, idiopathic	S	5	48	13 348	45 674	610	4141	3.23	21.92	0.37	7	10
Asthma	Μ	6	3	150 528	3799	572	4713	3.03	24.95	0.09	7	7
Hypoplastic left heart syndrome	S	7	63	5415	104 037	563	5277	2.98	27.93	0.07	5	7
Bronchiolitis	Μ	8	4	107 562	5225	562	5839	2.98	30.91	0.04	6	2
Hypertrophy of tonsils and adenoids	S	9	2	225 758	2468	557	6396	2.95	33.86	0.30	12	8
Extreme immaturity, birth weight 500-749 g	Μ	10	72	2302	199 808	460	6856	2.44	36.30	0.03	3	3
Transposition of great vessels	S	11	61	6530	66 344	433	7289	2.29	38.59	0.05	4	6
Extreme immaturity, birth weight 750-999 q	Μ	12	71	2318	177 915	412	7701	2.18	40.77	0.04	3	5
Necrotizing enterocolitis	M/S	13	68	2781	132 236	368	8069	1.95	42.72	0.04	3	5
Tetralogy of Fallot	S	14	62	6107	59 327	362	8431	1.92	44.64	0.08	5	7
Cellulitis	Μ	15	8	79 288	4532	359	8791	1.90	46.54	0.05	8	3
Specified conditions originating in perinatal period, other	Μ	16	43	14 973	23 199	347	9138	1.84	48.38	0.04	1	3
Septicemia	М	17	54	9496	35 506	337	9475	1.79	50.16	0.01	2	3
Acute lymphoid leukemia without remission	Μ	18	49	13 339	22 757	304	9779	1.61	51.77	0.09	9	11
Otitis media, unspecified	S	19	1	227 700	1322	301	10 080	1.59	53.36	0.22	9	12
Coarctation of aorta or interrupted aortic arch	S	20	59	6674	44 484	297	10377	1.57	54.94	0.06	5	9
Cystic fibrosis Congenital anomalies of abdominal wall, other	M S	21 22	51 69	12 790 2775	21 973 98 057	281 272	10 658 10 930	1.49 1.44	56.42 57.86	0.14 0.09	7 8	6 6
Gastroesophageal reflux and esophagitis	M/S	23	10	59 139	4404	260	11 190	1.38	59.24	0.03	14	5
Acute appendicitis without peritonitis	S	24	16	40 142	6373	256	11 446	1.35	60.60	0.19	7	8
Ventricular septal defect	S	25	58	6869	36 839	253	11 699	1.34	61.94	0.11	4	8

(continued)

Table. Prevalence, Cost, and Variation in Standardized Cost for the 50 Most Prevalent and 50 Most Costly Pediatric Inpatient Conditions (continued)

			Rank		Standardized Cost, \$			Standar All 495	dized Cost for Conditions, %		Ou Hospita	tlier Ils, No.ª
Condition	Туре	Cost Pr	Prevalence	Encounters, No.	Per Encounter	Total, Millions	Cumulative, Millions	Total	Cumulative	ICC ^a	Low- Cost	High- Cost
Mechanical complication of nervous system device, implant, and graft	S	26	26	22 046	11 418	252	11 951	1.33	63.27	0.07	4	3
Dental caries	S	27	6	102 523	2398	246	12 197	1.30	64 57	0.22	5	13
Sickle cell disease with crisis	M	28	20	30 963	7769	241	12 437	1.27	65.85	0.09	5	7
Endocardial cushion defects, other	S	29	65	4180	55 038	230	12 667	1.22	67.06	0.07	4	10
Infection and inflammation due to vascular device, implant, or graft	M/S	30	52	10914	20 656	225	12 893	1.19	68.26	0.05	2	6
Neutropenia	Μ	31	28	21 720	10260	223	13 116	1.18	69.44	0.04	3	4
Preterm infants, birth weight 1000-1249 g, other	Μ	32	75	2083	104 755	218	13 334	1.16	70.59	0.12	3	5
Urinary tract infection	Μ	33	15	40 393	5399	218	13 552	1.15	71.75	0.06	7	4
Acute myeloid leukemia without remission	Μ	34	66	3521	61 176	215	13 767	1.14	72.89	0.11	10	8
Seizures with and without intractable epilepsy	Μ	35	19	31 009	6856	213	13 980	1.13	74.01	0.04	7	3
Dehydration	Μ	36	11	52 970	3753	199	14 179	1.05	75.06	0.07	9	6
Other convulsions Aspiration pneumonia or pneumonitis	M M	37 38	14 55	42 222 8920	4693 20 858	198 186	14 377 14 563	1.05 0.98	76.11 77.10	0.06 0.04	9 1	3 5
Respiratory problems after birth, other	Μ	39	53	9833	18 855	185	14 748	0.98	78.08	0.09	8	3
Acute appendicitis with peritonitis	S	40	41	15 606	11 824	185	14 933	0.98	79.06	0.14	5	6
Congenital anomalies of skull and face bones	S	41	56	8661	21 294	184	15 117	0.98	80.03	0.14	7	8
Patent ductus arteriosus	S	42	60	6597	27 102	179	15 296	0.95	80.98	0.19	8	8
Congestive heart failure	Μ	43	67	2990	57 911	173	15 469	0.92	81.90	0.05	4	7
Anomalies of diaphragm, congenital	S	44	76	1874	84 524	158	15 628	0.84	82.74	0.08	4	6
Perinatal chronic respiratory disease	М	45	70	2333	67 772	158	15 786	0.84	83.57	0.05	4	8
Diabetic ketoacidosis	М	46	22	25 352	6172	156	15 942	0.83	84.40	0.19	7	8
Preterm infants, birth weight 1250-1499 g, other	Μ	47	73	2204	70742	156	16 098	0.83	85.23	0.11	5	3

(continued)

Table. Prevalence, Cost, and Variation in Standardized Cost for the 50 Most Prevalent and 50 Most Costly Pediatric Inpatient Conditions (continued)

			Rank		Standardized Cost, \$			Standar All 495	dized Cost for Conditions, %		Ou Hospita	tlier Ils, No.ª
Condition	Туре	Cost	Prevalence	Encounters, No.	Per Encounter	Total, Millions	Cumulative, Millions	Total	Cumulative	ICC ^a	Low- Cost	High- Cost
Inguinal hernia, unilateral or bilateral, nonobstructive	S	48	9	61 645	2497	154	16 252	0.81	86.04	0.25	14	10
Respiratory failure of newborn	М	49	74	2144	71 695	154	16 406	0.81	86.86	0.05	3	7
Partial anomalous pulmonary venous connection	S	50	64	4304	35 312	152	16 558	0.80	87.66	0.06	3	5
Fever	М	51	18	33 056	4558	151	16 708	0.80	88.46	0.05	7	4
Failure to thrive	Μ	53	38	16776	8081	136	16 983	0.72	89.91	0.04	4	5
Partial epilepsy with or without intractable epilepsy	Μ	54	47	13 388	9345	125	17 108	0.66	90.57	0.04	2	4
Abdominal pain	Μ	56	13	43 127	2737	118	17 346	0.62	91.83	0.09	15	8
Feeding difficulties and misman- agement	Μ	57	50	13 300	8364	111	17 458	0.59	92.42	0.05	6	5
Vesicoureteral reflux unspecified or without reflux nephropathy	S	58	33	18 498	5645	104	17 562	0.55	92.98	0.23	7	6
Supracondylar fracture of humerus	S	59	21	26 473	3889	103	17 665	0.55	93.52	0.11	7	8
Gastroenteritis, infectious	Μ	60	24	24 246	4147	101	17 766	0.53	94.05	0.08	6	7
Congenital hypertrophic pyloric stenosis	S	61	39	16755	5720	96	17 861	0.51	94.56	0.17	10	6
Cleft palate or cleft lip	S	62	40	16368	5685	93	17 954	0.49	95.05	0.31	8	11
Gastroenteritis and colitis, noninfectious	Μ	63	25	23 198	3549	82	18 037	0.44	95.49	0.07	12	8
Esotropia, exotropia, heterotropia, and hypertropia	S	64	17	35 364	2201	78	18 115	0.41	95.90	0.34	6	9
Hypospadias	S	65	30	20 498	3624	74	18 189	0.39	96.30	0.37	10	8
Redundant prepuce and phimosis	S	66	12	43 754	1694	74	18 263	0.39	96.69	0.00	7	10
Upper respiratory tract infection	Μ	67	32	19223	3848	74	18 337	0.39	97.08	0.06	6	6
Constipation, unspecified	М	68	31	20 378	3587	73	18 410	0.39	97.47	0.07	9	5
Viral infection, unspecified	М	69	34	17 794	4003	71	18 481	0.38	97.84	0.07	6	4
Undescended testis	S	70	23	25 082	2645	66	18 548	0.35	98.19	0.31	10	7
Viral meningitis Gastritis, gastroduode- nitis, without hemorrhage, unspecified	M M	71 72	46 27	13 611 21 908	4672 2582	64 57	18 611 18 668	0.34 0.30	98.53 98.83	0.09 0.13	5 17	6 13

(continued)

Table. Prevalence, Cost, and Variation in Standardized Cost for the 50 Most Prevalent and 50 Most Costly Pediatric Inpatient Conditions (continued)

Condition	Туре		Rank	Standardized Cost, \$ All 495 Condition		dized Cost for Conditions, %		Outlier Hospitals, No.ª				
		Cost	Prevalence	Encounters, No.	Per Encounter	Total, Millions	Cumulative, Millions	Total	Cumulative	ICC ^a	Low- Cost	High- Cost
Neonatal hyperbilirubi- nemia	М	73	35	17 774	3074	55	18 723	0.29	99.12	0.06	6	4
Croup	М	74	29	20 861	2381	50	18772	0.26	99.38	0.08	13	4
Vomiting alone	Μ	75	45	13671	3192	44	18 816	0.23	99.61	0.07	14	5
Encounter for removal of internal fixation device	S	76	44	14 591	2530	37	18 853	0.20	99.81	0.21	9	7
Umbilical hernia without mention of obstruction or gangrene	S	77	36	17 091	2108	36	18 889	0.19	100.00	0.27	9	9

Abbreviations: ICC, intraclass correlation coefficient; M, medical; S, surgical.

^a The ICCs and number of outlier hospitals were calculated from standardized costs adjusted for patient age (<30 days; ≥30 days and <1 year; ≥1 year and <5 years; ≥5 years and <13 years; ≥13 years and <17 years; ≥18 years), sex, race (white, black, other), presence of a complex chronic condition,¹² all patient refined diagnosis related group severity level, and patient type (inpatient, ambulatory surgery, and observation status).

encounter, even after adjusting for patient-level factors) included hypertrophy of the tonsils and adenoids requiring tonsillectomy and/or adenoidectomy, otitis media requiring tympanostomy tube placement, and acute appendicitis without peritonitis requiring appendectomy.

Looking more closely at acute appendicitis without peritonitis as an example of a condition that meets multiple high-priority criteria, we can see that it was indeed common (n = 40142 over 6 years; prevalence rank = 16),was costly (approximately \$11.5 billion over 6 years; standardized cost rank = 24), and had a high degree of interhospital variability in standardized costs per encounter (Figure 1). The ICC for this condition was 0.19, which means that 19% of all the variation in standardized cost per encounter could be attributed solely to the hospital in which these children happened to receive care. The outlier analysis for acute appendicitis without peritonitis (Figure 2) also demonstrated a high degree of interhospital variation in standardized costs. There was a 1.7-fold difference in mean cost per encounter between the 20th and 80th percentiles, and a total of 15 hospitals met outlier criteria-7 with more than 30% of encounters in the lowest cost quintile and 8 with more than 30% of encounters in the highest cost quintile.

COMMENT

Using detailed billing and administrative data from a consortium of 38 large freestanding children's hospitals, we generated inputs for several of the important conditionrelated criteria that both the IOM² and Dubois and Graff⁵ included in their CER prioritization frameworks. The approach required development of a grouper for combining encounters with similar principal discharge diagnosis and procedure codes and the creation of a CMI to standardize the unit costs for more than 22 000 CTC codes

in the PHIS database. We identified several surgical conditions that were prevalent and/or costly and displayed high variation in standardized cost per encounter even after adjustment for patient demographic characteristics and markers of severity of illness. Ten of our 77 prevalent and/or costly conditions appeared on the IOM's list of priority topics, including prematurity, dental caries, and asthma, but these conditions did not always display high interhospital variability in resource utilization. Although our analysis was limited to pediatric encounters, researchers can apply our methods and prioritization strategy to detailed administrative data collected in other care settings and adults. Both researchers and funding agencies can use the results of our analysis to decide which pediatric conditions should be prioritized for CER.

While differences in patient characteristics such as severity of illness, comorbidities, or disease stage at presentation might account for some of the high variation in resource utilization that we observed for specific conditions, we know from previous studies done using the PHIS database (for example, on osteomyelitis,¹⁴ complicated pneumonia,¹⁵ urinary tract infections,¹⁶ and antireflux surgery¹⁷) that hospital-specific differences in approaches to clinical management are important drivers of variation in resource utilization. Decisions about length of stay, location of care, use of specific medications, surgical vs medical approaches, and early vs late intervention often have major implications for resource utilization and patient outcomes. As others have found in hospital care for adults, some of this variation will reflect overuse of health care resources without clear benefits to patients, while some will reflect underuse of resources resulting in suboptimal patient outcomes. The implications of this unwarranted variation are 2-fold. In situations where a strong evidence base exists to sup-



Figure 1. Within- and across-hospital standardized costs per encounter for appendicitis without peritonitis (all included admissions had a procedure code for appendectomy). Boxes indicate interquartile range (25th-75th percentiles); center hatches, median (50th percentile); diamonds, mean; whiskers, minimum and maximum values within a range defined by the 25th percentile minus 1.5 (interquartile range) and the 75th percentile plus 1.5 (interquartile range); and circles, values outside this range.

port one management strategy over another, the variation represents an opportunity to standardize care across hospitals through quality improvement collaboratives, similar to those espoused by the Institute for Healthcare Improvement and Intermountain Healthcare.¹⁸ However, more often (and especially in pediatrics), this variation is a symptom of major evidence gaps regarding best practices and thus signals a need for more CER.

Our study has a few important limitations. First, our data and analyses were limited to discrete hospital encounters and did not include longitudinal costs of outpatient care or rehospitalization. Some of the prioritization rankings might have been quite different if we had incorporated longitudinal costs. Second, the hospitalization costs that we report do not reflect the true costs of providing care at each of the hospitals. We standardized unit costs and used total standardized costs as a surrogate measure for summarizing and comparing resource utilization across hospitals. Third, the PHIS database includes only freestanding tertiary care children's hospitals. It is possible that variation in costs across hospitals would have been even greater if smaller, general, and community hospitals had been included, where the intensity of care is often lower.



Figure 2. Distribution of hospitals' standardized costs per encounter for appendicitis without peritonitis (all included encounters had a procedure code for appendectomy) according to overall quintiles of standardized costs. Overall quintiles are defined by standardized cost per encounter for all patients with appendicitis without peritonitis across all hospitals. Hospitals toward the top had a higher proportion of encounters with standardized costs in the lowest quintiles, while hospitals toward the bottom had a higher proportion of encounters with standardized costs in the lowest quintiles, while hospitals toward the bottom had a higher proportion of encounters with standardized costs in the fifth quintile and approximately 20% of encounters with standardized costs in the fourth quintile.

How can these results be used to inform prioritization of CER topics? First, our methods can be applied to other administrative data sets to generate inputs for prioritization in adult medical care and in the outpatient setting. Second, our estimates of prevalence, cost, and variability in resource utilization for pediatric hospital conditions can be used as inputs for funding agencies such as the Patient-Centered Outcomes Research Institute in their prioritization of pediatric conditions for CER. It must be recognized, of course, that other condition-related criteria need to be considered in any prioritization effort, including variation in outcomes and the level of current evidence for any specific condition. As outlined in Dubois and Graff's prioritization framework, there are also research-related criteria that must be considered, including the cost and time required to complete the research, the probability of research success, and the likelihood that the research findings would be adopted into practice. After high-priority conditions are selected, we must identify the specific CER questions related to those conditions most in need of answers.

CONCLUSIONS

Comparative effectiveness research aims to produce generalizable knowledge about the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition or to improve the delivery of care. Pediatric populations have special potential to benefit from this type of research as there is a paucity of evidence to support the safety and efficacy of medications, procedures, and medical devices in children.⁴ The Patient-Centered Outcomes Research Institute and other organizations can use our methods and the results of our pediatric-focused analysis to generate inputs for the prioritization frameworks they will use to assemble their CER portfolios.

Accepted for Publication: May 3, 2012.

Published Online: October 1, 2012. doi:10.1001 /archpediatrics.2012.1266

Author Affiliations: Division of General Pediatrics, Center for Pediatric Clinical Effectiveness, Children's Hos-

pital of Philadelphia (Drs Keren, Localio, McLeod, and Dai and Mr Luan) and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine (Drs Keren and Localio), Philadelphia; Children's Hospital Association, Overland Park, Kansas (Dr Hall); and Division of Inpatient Medicine, Department of Pediatrics, University of Utah Health Sciences Center, and Primary Children's Medical Center and Institute for Healthcare Delivery Research, Intermountain Healthcare, Salt Lake City (Dr Srivastava).

Correspondence: Ron Keren, MD, MPH, Division of General Pediatrics, Children's Hospital of Philadelphia, 3535 Market St, Room 1524, Philadelphia, PA 19104 (keren @email.chop.edu).

Author Contributions: All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. *Study concept and design*: Keren, Luan, Localio, Hall, McLeod, and Srivastava. *Acquisition of data*: Keren, Luan, Hall, and Dai. *Analysis and interpretation of data*: Keren, Luan, Localio, Hall, McLeod, and Dai. *Drafting of the manuscript*: Keren, Localio, and Hall. *Critical revision of the manuscript for important intellectual content*: Keren, Luan, Localio, McLeod, Dai, and Srivastava. *Statistical analysis*: Keren, Luan, Localio, Hall, and Dai. *Obtained funding*: Keren and Srivastava. *Administrative, technical, and material support*: Keren, Luan, and McLeod. *Study supervision*: Keren, Luan, Localio, and Srivastava.

Pediatric Research in Inpatient Settings (PRIS) Network Investigators: Sanjay Mahant, MD, MSc, Patrick Conway, MD, MSCE, Christopher Landrigan, MD, MPH, Tamara Simon, MD, MSPH, Samir Shah, MD, MSCE, Karen Wilson, MD, MPH, and Joel Tieder, MD, MPH.

Financial Disclosure: Dr Keren has served as a paid member of the Data Safety and Monitoring Board for Tengion Inc and has provided consultation in medical malpractice cases. Dr Localio is an associate editor of the *Annals of Internal Medicine*, which receives and considers similar manuscripts regularly. Dr Srivastava has provided consultation in medical malpractice cases.

Funding/Support: This work was supported by Health Research Formula Grant 4100050891 from the Pennsylvania Department of Public Health Commonwealth Universal Research Enhancement Program and a grant from the Child Health Corporation of America.

Additional Contributions: Debra Hillman, MS, and Jaime Blank, MSHS, provided overall project management for this research effort. The Pediatric Research in Inpatient Settings (PRIS) Executive Council (Sanjay Mahant, MD, MSc, Patrick Conway, MD, MSCE, Christopher Landrigan, MD, MPH, Tamara Simon, MD, MSPH, Samir Shah, MD, MSCE, Karen Wilson, MD, MPH, and Joel Tieder, MD, MPH) reviewed procedure codes to further restrict the cohort of children within the medical and surgical conditions.

REFERENCES

- Sox HC. Comparative effectiveness research: a progress report. Ann Intern Med. 2010;153(7):469-472.
- 2. Institute of Medicine. *Initial National Priorities for Comparative Effectiveness Research*. Washington, DC: Institute of Medicine; 2009.
- US Department of Health and Human Services. Federal Coordinating Council for Comparative Effectiveness Research: Report to the President and the Congress, June 30, 2009. Washington, DC: US Dept of Health & Human Services; 2009.
- Simpson LA, Peterson L, Lannon CM, et al. Special challenges in comparative effectiveness research on children's and adolescents' health. *Health Aff (Millwood)*. 2010;29(10):1849-1856.
- Dubois RW, Graff JS. Setting priorities for comparative effectiveness research: from assessing public health benefits to being open with the public. *Health Aff* (*Millwood*). 2011;30(12):2235-2242.
- Simon TD, Berry J, Feudtner C, et al. Children with complex chronic conditions in inpatient hospital settings in the United States. *Pediatrics*. 2010;126(4):647-655.
- Mongelluzzo J, Mohamad Z, Ten Have TR, Shah SS. Corticosteroids and mortality in children with bacterial meningitis. JAMA. 2008;299(17):2048-2055.
- Dartmouth Institute for Health Policy and Clinical Practice. The Dartmouth Atlas of Health Care. http://www.dartmouthatlas.org/. Accessed May 2, 2012.
- Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending, part 2: health outcomes and satisfaction with care. *Ann Intern Med.* 2003;138(4):288-298.
- US Bureau of Labor Statistics. Consumer Price Index. http://www.bls.gov/cpi/. Accessed September 16, 2011.
- Schafer JL. Multiple imputation: a primer. Stat Methods Med Res. 1999;8(1):3-15.
- Feudtner C, Christakis DA, Connell FA. Pediatric deaths attributable to complex chronic conditions: a population-based study of Washington State, 1980-1997. *Pediatrics*. 2000;106(1, pt 2):205-209.
- Fox D, Morrato E, Campagna EJ, et al. Outcomes of laparoscopic vs open fundoplication in children's hospitals: 2005-2008. *Pediatrics*. 2011;127(5):872-880.
- Zaoutis T, Localio AR, Leckerman K, Saddlemire S, Bertoch D, Keren R. Prolonged intravenous therapy vs early transition to oral antimicrobial therapy for acute osteomyelitis in children. *Pediatrics*. 2009;123(2):636-642.
- Shah SS, Hall M, Newland JG, et al. Comparative effectiveness of pleural drainage procedures for the treatment of complicated pneumonia in childhood. *J Hosp Med.* 2011;6(5):256-263.
- Conway PH, Keren R. Factors associated with variability in outcomes for children hospitalized with urinary tract infection. J Pediatr. 2009;154(6):789-796.
- Srivastava R, Berry JG, Hall M, et al. Reflux related hospital admissions after fundoplication in children with neurological impairment: retrospective cohort study. *BMJ*. 2009;339:b4411.
- James BC, Savitz LA. How Intermountain trimmed health care costs through robust quality improvement efforts. *Health Aff (Millwood)*. 2011;30(6):1185-1191.

WWW.ARCHPEDIATRICS.COM